BACKGROUND AND AIM: Silicone breast implants have, for a long time, been considered as biologically inert and harmless. However the relationship between silicone breast implants and the risk of autoimmune diseases has generated intense medical interest. The aim of our review is to summarize the data linking silicone breast implants and autoimmune diseases, including the most recent association with autoimmune/inflammatory syndrome induced by adjuvants (ASIA). METHODS: The clinical research included articles from the last 16 years using the MeSH terms "breast implants" and "autoimmune diseases" and also the following terms: "autoimmune/inflammatory syndrome induced by adjuvants" and "Shoenfeld's syndrome". The Oxford 2011 Levels of Evidence was used to assign a level-of-evidence. Eligible articles included those who described a population of adult women (>17 years), which have breast implants versus women without implants. The clinical outcome measured was the development of an autoimmune disease. RESULTS: Of the 268 obtained articles, five matched eligibility criteria (one meta-analysis, two systematic reviews and two cohort studies). Results show that although studies could not confirm an association between silicone breast implants and classical autoimmune diseases, a few studies demonstrated an association between implants and undefined symptoms such as fatigue, arthralgia, myalgia and cognitive symptoms, which resembled a newly introduced syndrome, known as ASIA. CONCLUSIONS: Evidence remains inconclusive about any association between silicone breast implants and classical autoimmune diseases. ASIA seems to be linked to previous exposition to an adjuvant such as silicone. However, we will need better evidence from large studies with accurate methodology to determine whether any true association exists between ASIA syndrome and silicone breast implants.
INTRODUCTION
Breast implants (BI) have for a long time, been considered as biologically inert and harmless. However, from 1992 to 2006, the Food and Drug Administration (FDA) restricted their use due to controversy about their safety. 1 When the FDA approved silicone gel-filled BI in the United States, in 2006, it recognized that there were limited data on rare events and long-term outcomes, so required each company to design and conduct post-approval studies as conditions of approval. 2 Local complications and adverse outcomes included capsular contracture, reoperation, implant rupture, wrinkling, asymmetry, scarring, pain and infection; however these complications were consistent with those noticed at the time of the approval. 2, 3 Implant removal was also described and the longer the women had silicone gel-filled BI, the more likely was to experience local complications or adverse outcomes. 2 In what concerns to extended complications, although an association with systemic diseases was never established, women continuously blamed implants for their unexplained symptoms. 3 The question whether silicone BI can cause serious systemic health problems has often been posed but seldom thoroughly answered. 3 According to the FDA Update on the Safety of Silicone Gel-Filled Breast Implants, over studies with 8 to 10 years of follow-up, there have been some diagnoses of connective tissue disease (CTD) and autoimmune or rheumatic diseases. These included cases of fibromyalgia, Raynaud's syndrome (RS), rheumatoid or inflammatory arthritis, systemic lupus erythematosus (SLE), thyroid-related disease, miscellaneous and unspecified CTD cases. Follow-up rates were considered low, so the FDA recognized that these studies had limitations, and did not provide the necessary data to definitively answer questions about rare associations and that the current literature did not support an association between CTD and silicone gel-filled BI. 2 However, a few studies demonstrated an association between implants and undefined symptoms such as fatigue, arthralgia, myalgia and cognitive symptoms. 3 Other authors reported a symptom pattern in patients with silicone BI that mimic autoimmune. 3 In the 1990s this even lead to the introduction of a new disease called "siliconosis" or "silicone reactive disorder" with symptoms such as memory loss, fever morning stiffness, paraesthesia, hair loss, sweating and joint pain. 3 Later, a syndrome called "autoimmune/inflammatory syndrome induced by adjuvants" (ASIA) or Shoenfeld's syndrome was introduced. 3 This autoimmune/inflammatory syndrome was proposed on 2011 by Shoenfeld et al and includes five conditions linked to previous exposure to an adjuvant substance, one of which could be silicone, suggesting an association between environmental factors and induction of autoimmunity and loss of tolerance. 4 A long time after the first description of this relationship, Colaris MJ et al recognized the development of a specific entity that cannot be classified as a classic CTD, thus proposing label these patients as suf-fering from ASIA due to 'Silicone Implant Incompatibility Syndrome' (SIIS). 5 In 2013, Tervaert JW et al described a case series of 32 women with silicone BI who had silicone implant incompatibility syndrome and complaints fulfilling the diagnostic criteria of ASIA. Furthermore, 17 of them were classified as suffering from a systemic autoimmune disease and seven patients from an organ-specific autoimmune disease. 6 Shoenfeld's criteria for ASIA include four major and four minor criteria, and patients were considered having the syndrome when either two major or one major and two minor criteria were present. Therefore, major criteria were: exposure to an external stimulus (infection, vaccine, silicone, adjuvant) prior to clinical manifestations; the appearance of 'typical' clinical manifestations: myalgia, myositis or muscle weakness, arthralgia and/or arthritis, chronic fatigue, unrefreshing sleep or sleep disturbances, neurological manifestations (especially associated with demyelination), cognitive impairment, memory loss, pyrexia or dry mouth; the removal of inciting agent induces improvement; typical biopsy of involved organs. The four minor criteria established were: the appearance of autoantibodies or antibodies directed at the suspected adjuvant; other clinical manifestations (i.e. irritable bowel syndrome); specific HLA (i.e. HLA DRB1, HLA DQB1); evolvement of an autoimmune disease (i.e. multiple sclerosis, systemic sclerosis). 5 There are some authors that recognize the association, but they consider a definition of those women who might harbor an increased risk for this disease. They believe that there are four groups of patients sharing predisposition to the development of silicone-induced ASIA: patients with prior documented autoimmune reaction to an adjuvant (e.g. vaccination); patients with established autoimmune conditions; patients with history of allergic conditions/atopic disorders; and individuals who are prone to develop autoimmunity (genetic predisposition and/or relevant environmental triggers). 7 Although most studies could not undoubtedly confirm or deny an association between implants and CTD or autoimmune diseases, this relationship remains under intense debate. 3, 8 Due to the controversy about their safety, the authors decided to do a systematic review to summarize the data linking silicone BI and autoimmune diseases, including the most recent association with ASIA.
METHODS
A clinical research was conducted including articles from the last 16 years, in Portuguese and English languages, using the MeSH terms "breast implants" and "autoimmune diseases" and also the following terms: "ASIAautoimmune/inflammatory syndrome induced by adjuvants" and "Shoenfeld's syndrome".
The literature searches were done in MEDLINE databases, National Clearinghouse, Canadian Medical Association Practice Guidelines InfoBase, Guidelines Finder of the National Electronic Library for Health in the British NHS, Database of Abstracts of Reviews of Effectiveness -Centre for Reviews and Dissemination, Bandolier and The Cochrane Library.
We used the Oxford 2011 Levels of Evidence to assign a level-of-evidence (LE). Eligible articles included those who described a population of adult women (>17 years), which have breast implants versus women without implants. The clinical outcome measured was the development of an autoimmune disease, including the most recent linking with ASIA or "Shoenfeld's syndrome".
Of the 268 obtained articles, five matched eligibility criteria (one meta-analysis, two systematic reviews and two cohort studies). Of these, 263 were excluded after title reading (n=192), abstract reading (n=29) and since they were repeated articles (n=42) (Fig. 1 ).
SYNTHESIS OF RESULTS:
58 studies (in five publications) met eligibility criteria. Therefore, the relation between silicone BI and autoimmune diseases (such as rheumatoid arthritis (RA), Sjögren's syndrome (SjS), RS, dermatomyositis and polymyositis, fibromyalgia, sarcoidosis, SLE, CTD) is a question that reveals different conclusions obtained so far with a consensus trend towards no increased risk of this association, which can lead to a lack of a fully answer to this question. Thus, in recent years, silicone prostheses were possibly associated with ASIA, 
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in some cases even with life-threatening outcomes. However, the evidence between this association remains inconclusive and several more studies are needed to assign a better LE.
RISK OF BIAS ACROSS STUDIES:
studies included had differences in study design, clinical endpoints, definitions and patient populations. Yet, the evidence was most frequently not specific to silicone BI. Last but not least, low patient follow-up rates limited drawing definitive conclusions.
No additional analyses were done.
RESULTS
Janowsky EC et al 8 study included nine cohort studies (CS), nine case-control studies (CCS) and two cross-sectional studies (CSC). A meta-analysis of the results of these articles was conducted, with and without adjustment for confounding factors and a separate analysis restricted to studies of silicone BI. It was also estimated the annual number of new cases of connective-tissue disease that could be a consequence of the use of BI. The CS, the CSC and one CCS evaluated multiple diseases outcomes (Table 1) . Several diseases were studied: RA, SLE, scleroderma or systemic sclerosis (SS), SjS, dermatomyositis or polymyositis, all definitive connective tissue combined and a category of other autoimmune or rheumatic conditions. Rheumatic conditions included undifferentiated CTD or mixed CTD that did not fulfill the diagnostic criteria of classic autoimmune diseases or signs and symptoms of autoimmune or rheumatic conditions, such as joint pain, swelling or both.
Janowsky EC et al used several techniques of meta-analyses which included exact methods (unadjusted analysis) and approximate, large-sample methods (adjusted analysis). These authors also considered study results that included only silicone-gel-filled implants. There is no evidence, in either analysis of unadjusted odds ratios or the analysis of adjusted relative risks (RR), excluding the results of the study by Hennekens et al, 9 of a significantly increased risk of any specific CTD, all definite CTD combined or other autoimmune or rheumatoid conditions, as it can be seen on Table 1 .
Nor was there evidence of significantly increased risk in the unadjusted analyses or in analysis restricted to silicone gel BI. The meta-analyses focusing solely on silicone-gel BI produced lower summary estimates of the adjusted RR for all diseases than did the analysis based on all types of BI. It can be noticed that relative risk for SjS was high (RR: 1.42; 95% confidence interval (CI): 0.65 to 3.11) but this diagnosis requires salivary-gland biopsy and this information is unknown, so it may have bias in estimated adjusted RR's size.
Authors concluded that there was no evidence of an association between BI in general, or silicone-gel BI, and any of the individual CTD, all CTD combined or other autoimmune or rheumatic conditions. BI have a minimal effect on the number of women in whom CTD develop and the elimination of implants would not be likely to reduce the incidence of CTD.
The study of Balk EM et al 1 had the purpose to systematically review the literature regarding specific long-term health outcomes in women with silicone gel BI, including: cancer, connective tissue, rheumatologic and autoimmune diseases, neurologic diseases, reproductive issues (including lactation), offspring issues and mental health issues (depression and suicide) ( Table 2 ). Studies of any longitudinal design were included and compared women with and without BI. These articles included women with any history of silicone gel BI (excluding injected silicone), silicone tissue expanders and recall implants produced by Poly Implant Prothèse. This review took place under contract with Plastic Surgery Foundation.
Of the 32 studies included, we will just examine the ones related to CTD. These studies found an increased risk for RA and SjS, and possibly RS, but no associations with others CTD. Nevertheless, the evidence is inadequate to determine whether silicone gel BI affect the risk for these diseases because few analysis were adequately adjusted for many confounders. The results are summarized on Table 2 .
These authors concluded that, despite numerous studies reporting on the risk of many diseases and conditions, evidence was insufficient for an association between BI and any health outcome, including CTD. Furthermore, most of studies analyzed all BI, so their findings are not specific for silicone gel BI. No outcome had at least two adequately adjusted studies that yielded consistent estimates of associations. Owing the flaws and inconsistencies among the studies reviewed, further investigation is required whether any true association exist between silicone gel BI and long term health outcomes.
The aim of the Luis J. Jara et al 4 study was to systematically review the literature of severe ASIA cases. Articles published from 2011 to 2016 were included and this was the first study which analyzed all cases published of ASIA with severe manifestations. Severe ASIA was arbitrarily defined as major organ involvement, life-threatening conditions, intensive treatment, disability, hospitalization and outcome (survival and death).
They identified 4479 ASIA cases, 305 of which fulfilled arbitrary criteria of severe ASIA and 11 resulted in death. The majority of severe ASIA cases were related to human papillomavirus (HPV) vaccine, silicone, influenza vaccine and mineral oil injections. We will just examine silicone related results ( Table 2 ). The most affected organs were skin (17.7%), musculoskeletal tissue (14.43%), thyroid (13.77%), nervous system (13.22%) and gastrointestinal system (12.79%). Death causes related on this study were due to mineral oil injections (three patients), silicone (one patient which committed suicide) and seven due to HPV vaccine (not specified). The majority of severe ASIA cases were associated with silicone BI followed by HPV vaccine. The new case reports and cohort studies suggest an association between silicone BI with ASIA development, particularly after prosthesis rupture. In Luis J. Jara et al study, of the 130 ASIA cases related to silicone, 13 were considered severe ASIA, eight of these had prosthesis rupture and one committed suicide.
The authors concluded that efforts should be done to identify connections between adjuvants, autoimmunity and autoimmune diseases, whereas there's an increase in severe and life-threatening ASIA cases.
Maijers MC et al
3 conducted a descriptive cohort study and their aim was to collect a cohort of women with silicone BI and unexplained systemic symptoms to identify a possible pattern and compare it with ASIA (Table 3) . They included 80 women with silicone BI and unexplained systemic symptoms. All of them were examined by experienced consultant physicians and interviewed. Also, chest radiography (to exclude sarcoidosis) and laboratory tests were performed (C-reactive protein, hemoglobin, thrombocytes, leucocytes with differentiation, renal function and liver enzymes). The median age of women established was 47 years, 89% had silicone BI for cosmetic reasons and the median total exposure time to silicone was 14.5 years. Most women (75%) with silicone BI and unexplained systemic symptoms had pre--existent allergy prior to implantation, suggesting that intolerance to silicone or other substances in the implants might cause these symptoms. After a symptom-free period of years (median of 4.5 years), 65% developed systemic symptoms, most frequently fatigue, neurasthenia, joint pain, muscle pain, morning stiffness, night sweats and dyspnea. When classified according to the ASIA criteria, all women had at least two major criteria and 79% of women even fulfilled three or more typical clinical criteria ASIA manifestations. Because of the unexplained symptoms, 52 out of 80 women had an explantation of their BI. Among these 52 women, 36 reported a significant decrease of their symptoms, whereas nine of these 36 women stated that their symptoms had completely disappeared.
These study results align the hypothesis that silicone or other chemical substances in the implants may cause systemic symptoms in women with atopy or hyperimmune state. Although they had noticed a significant improvement in many patients after explantation, these results should be interpreted with caution because there was no control group. Therefore, in conclusion physicians should recognize this pattern and consider referring patients for explantation.
Colaris et al 5 cohort study compared 100 patients with ASIA criteria due to SIIS (the Maastricht cohort) diagnosed in 2014, with the Baylor College cohort (composed of 100 patients with adjuvant breast disease diagnosed between 1985 and 1992) and 18 other large cohorts of patients. The goal was to determine whether the spectrum of silicone-related disease changed during the last 30 years and whether ASIA due to SIIS was actually the same disease as the previously described adjuvant breast disease (Table 3 ).
In the Maastricht cohort, they analysed prospectively patients who developed complaints after receiving silicone gel-filled BI, using the Shoenfeld's criteria for the diagnosis of ASIA. The first consecutive hundred patients who fulfilled these criteria (two major or one major and two minor criteria) were included in this study. If explantation of silicone implants was performed, patients were reassessed to document possible changes of their clinical manifestations. This group was compared with the cohort described by Shoaib et al in 1994, constituted of 100 women with adjuvant breast disease, due to silicone breast implants or silicone fluid injections. 10 They concluded that the clinical manifestations between the cohorts were more or less identical, describing comparable frequencies of chronic fatigue, cognitive impairment, pyrexia, sicca complaints and severe neurological manifestations (especially associated with demyelination). However, the authors found significant differences between the two cohorts regarding myalgia, myositis or muscle weakness, arthralgia and/or arthritis, livedo reticularis and the occurrence of Raynaud's phenomenon, possibly due to differences in the diagnosis work-up. In the 2014 cohort, they also diagnosed 34 patients with an autoimmune disease (CTD, vasculitis, RA and others), whereas in the Baylor College cohort they did not describe any autoimmune disease. Besides, in the Maastricht cohort, 27 of 54 patients who underwent explantation of their silicone BI experienced improvement of their clinical manifestations, with a relapse of complaints after several weeks in seven patients. In the Baylor College cohort, 96 patients underwent explantation of the implant, but they did not describe the evolution of complaints. After comparing the Maastricht cohort and the Baylor College cohort with the 18 other large cohort studies, they concluded that a great similarity in complaints exists in all studies.
Author's findings suggest that, even with changes in the silicone implants composition in recent years, silicone remained a chronic stimulus to the immune system resulting in similar clinical manifestations between these cohorts. However, is still not clear if silicone BI are safe. • All women included where examined, interviewed, made chest radiography and laboratory tests.
• After a symptom-free period of years, 65% developed systemic symptoms.
• All had at least 2 major ASIA criteria and 79% fulfilled ≥3 typical clinical ASIA manifestations.
• Balk EM et al systematic review of 32 studies showed for most outcomes there was at most only a single adequately adjusted study, which usually found no significant associations. There were possible associations with increased risks for RA, SjS and RS.
The systematic review of Luis J. Jara et al was performed investigating severe ASIA cases. From 2011 to 2016, they identified 4479 ASIA cases, of them 305 fulfilled arbitrary criteria of severe ASIA including 11 deaths.
In the cohort study of Maijers MC et al 80 women were included, of which 75% reported pre-existent allergies. After a symptom-free period of years, a pattern of systemic symptoms developed, which included fatigue, neurasthenia, myalgia, arthralgia and morning stiffness in more than 65% of women. All had at least two major ASIA criteria and 79% fulfilled ≥3 typical clinical ASIA manifestations.
The cohort study of Colaris et al included two cohort groups: one with ASIA due to silicone implant incompatibility syndrome diagnosed in 2014 and the other with one hundred historical patients with adjuvant breast disease diagnosed between 1985 and 1992. Clinical manifestations between these studies were comparable.
Risk of bias across studies: some studies refer selection bias, since included women with BI and symptoms sought for medical care. Others refer that publication bias could be considered because studies that found no association were less likely to be published. Other considered bias to be related to the presence of inadequately adjusted studies, the unknown information regarding the diagnosis of specific diseases, (e.g. SjS which requires salivary-gland biopsy), the absence of control groups and small patient follow-up rates. Studies had yet differences in study design, clinical endpoints, definitions and patient populations.
DISCUSSION
We used techniques of systematic review to evaluate the existing studies of an association between breast implants and autoimmune diseases.
The results show that although studies could not confirm an association between silicone BI and classical autoimmune diseases, a few studies demonstrated an association between implants and undefined symptoms such as fatigue, arthralgia, myalgia and cognitive symptoms, which resembled a newly introduced syndrome, known as ASIA.
In the five included articles the evidence is not consensual.
Related to classical autoimmune diseases, the meta-analysis of Janowsky EC et al 8 concluded that there was no evidence of an association between silicone-gel BI and any of the autoimmune diseases.
The systematic review of Balk EM et al 1 showed an increased risk for RA, SjS and possibly RS but no associations with other diseases. Related to ASIA, the systematic review of Luis J. Jara et al 4 suggested an association between silicone BI with ASIA development, particularly after prosthesis rupture.
The cohort study of Maijers MC et al 3 showed that most women with silicone BI and unexplained systemic symptoms had pre-existent allergy prior to implantation, suggesting the hypothesis that silicone, or other chemical substances in the implants, may cause systemic symptoms in women with atopy or hyperimmune state. The cohort study of Colaris et al 5 reported a group of patients who developed complaints related to silicone BI, with the diagnostic criteria of ASIA.
However, the studies included in our review have some limitations. First of all, meta-analysis and systematic reviews are based on observational studies that are more susceptible to bias than clinical trials.
One other potential limitation of this review is the design of some studies, as women with silicone BI and unexplained symptoms visited the clinical on their own request, leading to selection bias.
Information on potential confounders of the association between BI and CTD was also incomplete in many studies. Specific genetic markers of susceptibility are recognized for some of the CTD, but no information on the basis of which to evaluate them was available in the epidemiologic studies. In addition, many studies did not report whether the indication for implantation was cosmetic or reconstructive, a difference that may have affected the signs and symptoms the subjects subsequently had.
Publication bias could be considered because studies that found no association between exposure and disease were less likely to be submitted and accepted for publication than were studies that found a positive association.
We realize that the present review has several limitations, but we believe that our findings may help physicians, such as general practitioners, plastic surgeons and internists, to recognize the systemic symptoms or unexplained symptoms pattern in women with silicone BI and so provide clinical information to enable a better practice and personal choice.
From a public health perspective, breast implants appear to have a minimal effect on the number of women in whom autoimmune diseases develop and elimination of implants would be unlikely to reduce the incidence of them.
CONCLUSION
Despite the controversy, evidence remains inconclusive about any association between BI and classical autoimmune diseases. We will need better evidence from large studies, with long time follow-up and with accurate methodology to determine whether any true association exists between ASIA syndrome and silicone breast implants.
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